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Peptidylarginine deiminases and extracellular vesicles: 
prospective drug targets and biomarkers in central 
nervous system diseases and repair
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Abstract  
Peptidylarginine deiminases are a family of calcium-activated enzymes with multifaceted 
roles in physiological and pathological processes, including in the central nervous system. 
Peptidylarginine deiminases cause post-translational deimination/citrullination, leading 
to changes in structure and function of a wide range of target proteins. Deimination 
can facilitate protein moonlighting, modify protein-protein interaction, cause protein 
dysfunction and induce inflammatory responses. Peptidylarginine deiminases also 
regulate the biogenesis of extracellular vesicles, which play important roles in cellular 
communication through transfer of extracellular vesicle-cargo, e.g., proteins and genetic 
material. Both peptidylarginine deiminases and extracellular vesicles are linked to a 
number of pathologies, including in the central nervous system, and their modulation with 
pharmacological peptidylarginine deiminase inhibitors have shown great promise in several 
in vitro and in vivo central nervous system disease models. Furthermore, extracellular 
vesicles derived from mesenchymal stem cells have been assessed for their therapeutic 
application in central nervous system injury. As circulating extracellular vesicles can be 
used as non-invasive liquid biopsies, their specific cargo-signatures (including deiminated 
proteins and microRNAs) may allow for disease “fingerprinting” and aid early central 
nervous system disease diagnosis, inform disease progression and response to therapy. 
This mini-review discusses recent advances in the field of peptidylarginine deiminase and 
extracellular vesicle research in the central nervous system, focusing on several central 
nervous system acute injury, degeneration and cancer models. 
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Introduction 
Peptidylarginine deiminases (PADs) are a family of calcium-
activated enzymes, with five isozymes identified in human 
(PAD1, PAD2, PAD3, PAD4 and PAD6), which play multiple roles 
in physiological and pathological processes, including in the 
central nervous system (CNS) (Moscarello et al., 1994; Lange 
et al., 2011, 2014;  Nicholas et al., 2014;  Ishigami et al., 2015; 
Caprariello et al., 2018; Faigle et al., 2019; Sancandi et al, 
2020). PADs cause post-translational modification of arginine 
to citrulline (deimination/citrullination), reducing net charge 
and increasing hydrophobicity of target proteins, leading to 
changes in protein structure and consequently protein-protein 
interactions. The different PAD isozymes display tissue-specific 
expression, with PAD2, PAD3 and PAD4 being the predominant 
isozymes of the CNS, and PADs furthermore differ in 
preference for target proteins. Intrinsically disordered proteins 
are most susceptible for deimination, alongside beta-sheets, 
and the position of the arginine also plays a role as arginines 
sitting next to aspartic acid residues are most prone to 
citrullination/deimination, while arginines flanked by proline 
or next to glutamic acid residues are rarely deiminated (György 
et al., 2006; Alghamdi et al., 2019). Deimination can affect a 
wide range of target proteins, ranging from mitochondrial, 
cytoplasmic, cytoskeletal and nuclear proteins (e.g., histones) 
and PADs are furthermore involved in extracellular vesicle 
(EV) release (Kholia et al., 2015; Lange et al., 2017a). The 
consequential modification of protein structure, caused 
by deimination, can lead to changes in protein-protein 
interactions and also facilitate protein moonlighting, a 
process which allows the same protein to carry out multiple 
autonomous and often unrelated functions and therefore 
contribute to multifaceted use of the same protein according 
to circumstantial requirements, both temporally and spatially, 
including in developmental processes, normal physiology and 
in pathological processes (Jeffrey et al., 2018). Deimination 
can though also cause protein denaturation and loss of protein 
function, and result in the generation of neo-epitopes, which 
can contribute to inflammatory and chronic inflammatory 
responses (György et al., 2006; Mondal and Thompson, 2018; 
Alghamdi et al., 2019). This mini-review discusses recent 
advances in the field of peptidylarginine deiminase and 
extracellular vesicle research in the central nervous system, 
highlighting research from our group on acute injury, 
neurodegeneration and brain cancer models. 
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Peptidylarginine Deiminases in Central Nervous 
System Injury and Disease
PADs have been reported to be associated with numerous 
neurodegenerative diseases (Nicholas et al., 2014; Ishigami et 
al., 2015; Lange et al., 2017b; Jang et al., 2018; Faigle et al., 
2019), CNS injury, regeneration and repair (Lange et al., 2011, 
2014; Lazarus et al., 2015; Attilio et al., 2017), as well as cancers 
of the CNS (Kosgodage et al., 2018; Uysal-Onganer et al., 2020). 
Furthermore, PADs have been described as a key regulator of 
EV release (Kholia et al., 2015; Kosgodage et al., 2018; Uysal-
Onganer et al., 2020), which not only plays roles in normal 
cell communication, but also is implicated in a number of 
chronic diseases, including cancer, in neurodegeneration and in 
regenerative pathways (Lange et al., 2017a; Sancandi et al., 2020; 
Uysal-Onganer et al., 2020). PAD-mediated effects on microRNA 
expression have also been identified in CNS degeneration and 
brain cancer (Sancandi et al., 2020; Uysal-Onganer et al., 2020). 
PAD-related pathways therefore offer novel avenues in targeting 
a range of CNS diseases, as well as being important players in 
CNS repair and regeneration (Figure 1).
Roles of Peptidylarginine Deiminases in Central 
Nervous System Development and 
Neurodegeneration
Roles for PADs in CNS development have been studied to 
some extent, particularly with relation to myelin basic protein 
during early development (Moscarello et al., 1994) and in 
the CNS in lower vertebrates by our group, indicating roles 
in ontogeny for tissue remodeling of nervous tissue in the 
spinal cord, brain and eye (Magnadottir et al., 2018). More 
emphasis has though been on research on pathological 
roles for PADs in the CNS, both in relation to acute injury 
and chronic conditions. Initially, PADs and associated protein 
deimination in the CNS was mainly investigated in relation to 
multiple sclerosis (MS), including assessment of PAD-mediated 
contribution to auto-inflammatory responses, which is an 
ongoing topic in MS research by several groups and may play 
major roles in MS (Caprariello et al., 2018; Faigle et al., 2019). 
Research on citrullination/deimination expanded to other 
areas, finding increasing evidence for significant roles of PADs 
in a number of other neurodegenerative diseases including 
Alzheimer’s disease (AD), frontotemporal dementia, prion 
diseases, amyotrophic lateral sclerosis and Parkinson’s disease 
(PD) (Nicholas et al., 2014; Ishigami et al., 2015; Lange et al., 
2017b; Jang et al., 2018). Many of the initial studies focused 
on post-mortem sample analysis, with a few target proteins 
for deimination being identified, including glial fibrillary acidic 
portein, while further understanding of pathways regulated by 
deimination required investigation. In vitro approaches by our 
group, using induced pluripotent stem cell neuronal models 
of patient derived fibroblasts carrying various mutations for 
frontotemporal dementia, amyotrophic lateral sclerosis and 
PD, furthermore confirmed that deimination patterns, as 
assessed by deiminated protein bands present in western blot 
analysis, were modified in these induced pluripotent stem cell 
models (Lange et al., 2017b), in accordance with increased 
deimination observed in previous studies using post-mortem 
samples from patients with AD, amyotrophic lateral sclerosis 
and PD. Most recently, our group carried out an in vivo study 
using a rat model of pre-motor PD, identifying PADs and 
protein deimination as hitherto unrecognized players in these 
early stages of PD. The study reported significantly increased 
deimination in the brain vasculature, changes in deiminated 
protein pathways relating to neurodegenerative pathways in 
plasma, in plasma EVs, as well as changes in circulating EV 
numbers and EV-microRNA cargo (Sancandi et al., 2020). 
Relevance of Peptidylarginine Deiminases and 
Extracellular Vesicles as Biomarkers
Deimination signatures in plasma and plasma-EVs, or in EVs 
isolated from other biofluids, may serve as liquid biopsies 
for biomarkers for detection of disease, disease progression 
and for developing intervention strategies at early stages of 
disease. Such signatures of deimination/citrullination may 
therefore provide considerable information. Given that PADs 
are a key modulator of EVs, which are membrane bound 
vesicles released from cells and carry protein and genetic 
cargo from the cell of origin and are therefore critical both 
in cellular communication as well as in disease progression, 
the roles for PADs and EVs may be closely linked in many 
pathologies. Furthermore, PAD-activation and resulting 
protein deimination, alongside EV biogenesis, are both 
calcium-dependent processes. Indeed, the “citrullinome” of 
selected neurodegenerative diseases, including MS and AD 
has for example recently been described to some degree by 
other groups (Gallart-Palau et al., 2016; Faigle et al., 2019), 
albeit not in EVs. Our group has recently identified that 
deiminated protein targets differ in plasma versus plasma-EVs 
in a rat model of early pre-motor PD, shedding light on EV-
mediated contributions to early changes in neurodegeneration 
and associated citrullinome “fingerprinting” (Sancandi et al., 
2020). Importantly, deimination signatures of both plasma and 
plasma-EVs identified in pre-motor PD were found to mirror 
early deimination changes observed in the brain-vasculature. 
Such deimination has not previously been described in 
pre-motor PD brains, until in our recent study, and was 
prominent in the brain vasculature in cortex, hippocampus 
and white matter, while deiminated histone H3 levels were 
significantly elevated in the dentate gyrus and cortex. While 
histone H3 is involved in gene regulation, it also contributes 
to extracellular trap formation (ETosis), which can act as a 
double edged sword in immunity by contributing to damage 
of own surrounding tissue. Upon analysis of deiminated 
proteins isolated from plasma and circulating plasma-EVs 
Figure 1 ｜ Schematic view of PAD-mediated processes in CNS pathologies. 
PADs are calcium catalyzed enzymes that cause conversion of ARG to 
citrulline, causing post-translational protein deimination and downstream 
pathways relating to CNS pathologies. Deimination causes changes in target 
protein structure and function, contributing to protein moonlighting and 
release of EVs. Depending on target proteins, deimination can affect gene 
regulation, mitochondrial function and generate neo-epitopes, contributing 
to inflammatory, including chronic inflammatory, responses. As deimination 
changes protein-protein interactions, this can influence protein networks in a 
range of CNS pathologies, as indicated by regulation of KEGG pathways via this 
post-translational modification. All the processes shown have been identified 
in various CNS pathologies by our group, including acute CNS injury and 
associated remodeling and repair, to neurodegenerative disease and in CNS 
cancer. ARG: Arginine; CNS: central nervous system; EV: extracellular vesicles; 
KEGG: kyoto encyclopedia of genes and genomes; PADs: peptidylarginine 
deiminases.
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from pre-motor PD animals, compared with control animals, 
KEGG pathways identified for deiminated proteins in the pre-
motor PD model were linked to AD, PD, Huntington’s disease, 
prion diseases, as well as for oxidative phosphorylation, 
thermogenesis, metabolic pathways, Staphylococcus aureus 
infection, gap junction, platelet activation, apelin signaling, 
retrograde endocannabinoid signaling, systemic lupus 
erythematosus and non-alcoholic fatty liver disease. These 
findings indicate PAD-mediated regulation of these pathways 
in neurodegeneration, both in plasma and via plasma-EVs. 
Identification of deimination signatures, which in the pre-
motor PD model were detectable at early disease stages 
before motor symptoms, therefore offers a novel non-
invasive blood-test which can also mirror the observed early 
brain vascular changes and reveals blood markers relating 
to neurodegenerative disease (Sancandi et al., 2020). As 
early diagnosis in neurodegenerative diseases is of pivotal 
importance, and biomarkers are scarce, the findings in the 
pre-motor PD model offer such novel markers and also pave 
the way for similar investigation in other neurodegenerative 
diseases, as deimination pathways in the PD model were 
also found to have some common factors with AD, prion 
disease, and Huntington’s disease (Sancandi et al., 2020). 
In AD, deimination targets have been identified to be sex 
related (Gallart-Palau et al., 2016) and such sex differences do 
warrant further exploration in other models of CNS disease. 
The role for PADs as regulators of EV release, alongside their 
roles in a number of neurodegenerative diseases including via 
the regulation of EVs and modulation of EV-cargo, highlights 
that this pathway may furthermore play critical roles to 
the contribution of neurodegenerative disease spread and 
progression via the prion-theory of EV-mediated distribution 
of misfolded proteins and other EV-cargo. In addition, PADs 
can contribute to neuroinflammation through the generation 
of deiminated neo-epitopes, via modification in gene-
regulation caused by histone deimination, as well as histone 
H3-mediated ETosis.  
Lessons from Animal Models 
In animal models of acute CNS injury, crucial roles for 
PADs have been revealed by us in spinal cord injury and 
associated regenerative capacity (Lange et al., 2011), as well 
as in neonatal hypoxic-ischemic encephalopathy (HIE) and 
related brain repair mechanisms (Lange et al., 2014). In the 
spinal cord, target cells of deimination were identified to 
be glia, neurones and oligodendrocytes, while detection of 
deiminated proteins by immunohistochemical analysis, in 
neonatal HIE, including for pan-deiminated proteins (F95 
antibody) and deiminated histone H3, was prominent in 
hippocampus and cortex, which include main areas affected by 
this type of insult (Lange et al., 2014). Studies by other groups 
have assessed PADs and deimination in traumatic and blast 
brain injury and reported that deimination of specific proteins 
was selective with respect to cell type and brain region, and 
may also contribute to autoimmune dysfunction in chronic 
pathology following head injury, including blast exposure 
(Lazarus et al., 2015; Attilio et al., 2017). Our studies on a pre-
motor PD rat model have furthermore revealed a new brain 
pathology at this early stage of PD, with significant increase 
in deiminated proteins detected in the brain vasculature, as 
well as circulating deiminated proteins in plasma and plasma-
EVs relating to neurodegenerative pathways (Sancandi et al., 
2020). In addition to using EVs as biomarkers, therapeutic 
approaches for using mesenchymal stromal/stem cell (MSC) 
derived EVs for aiding CNS repair have also been assessed 
(Ophelders et al., 2016; Dabrowska et al., 2019; Kodali et 
al., 2019), including by our group (Sisa et al., 2020). We 
showed that MSC application reduced neuroinflammation 
and provided significant neuroprotection in multiple brain 
regions and improved behavioral outcomes following severe 
HIE insult in a neonatal mouse model (Sisa et al., 2020). 
There is indeed a great interest in the potential of MSC-EVs 
for immunomodulation and tissue regeneration (Varderidou-
Minasian and Lorenowicz, 2020) and such strategies also 
provide scope for future in-depth studies in relation to CNS 
diseases and repair.
Peptidylarginine Deiminases and Extracellular 
Vesicles in Central Nervous System Cancer 
A recent focus of our research on PADs in the CNS has also 
been on cancers of the CNS, in particular glioblastoma 
multiforme (GBM), the most aggressive adult brain cancer 
with poor prognosis. We have reported differences in 
deiminated protein targets according to GBM cell lines, 
including differences in deimination of proteins involved 
in cancer progression and invasion. Furthermore, we have 
shown significant roles for PADs in the regulation and 
modulation of EV release profiles and on changes in EV-
mediated microRNA transport (Kosgodage et al., 2018; 
Uysal-Onganer et al., 2020). We identified that PAD isozyme-
specific expression varies between GBM cell lines, and that 
this correlates with different protein deimination signatures 
found between the GBM cell lines, therefore reflecting a 
fingerprint “citrullinome”, depending on brain cancer subtype. 
Importantly, these findings point to a significant contribution 
for PADs to the known heterogeneity of GBM tumors. 
Analysis of deiminated proteins identified that pathways 
for deiminated proteins relating to cancer, metabolism and 
inflammation differed between the two GBM cell lines; 
this included  HIF-1-, thyroid hormone synthesis-, viral-, 
necroptosis-, phagosome-, pentose phosphate-, pyruvate 
metabolism-, central carbon metabolism- and interleukin-17-
KEGG pathways (Uysal-Onganer et al., 2020). Furthermore, 
we identified that the different PAD isozymes (PAD2, PAD3 
and PAD4) differently regulated EV release  between GBM cell 
lines, as well as modulating EV microRNA-cargo relating to 
oncogenic signatures, and also differently affected GBM cell 
invasion (Onganer et al., 2020). Interestingly, we also found 
that the citrullinome of GBM cell lines differed depending 
on whether they were derived from male or female patients, 
although low experimental numbers need to be considered 
(Kosgodage et al., 2018; Uysal-Onganer et al., 2020). To what 
extent sex differences contribute to GBM heterogeneity, and 
the associated citrullinome, remains therefore to be further 
investigated in more GBM cell lines, including primary patient 
cell lines from different GBM tumors, also accounting for sex.
Peptidylarginine Deiminase Inhibitors
A range of PAD inhibitors have been developed in the previous 
decade by a number of laboratories for assessment in chronic 
disease pathologies relating to PADs, including MS, colitis, 
rheumatoid arthritis and cancers (Mondal and Thompson, 
2019). PAD inhibitors tested in relation to CNS disease and 
repair in our group have mainly focused on the pan-PAD 
inhibitor Cl-amidine, as well as PAD-isozyme specific inhibitors 
against PAD2 (AMF30a), PAD3 (Cl4-amidine) and PAD4 (GSK-
199), and these pharmacological PAD inhibitors have all been 
developed by the Thompson laboratory (UMASS Medical 
School; Mondal and Thompson, 2019). For this purpose, 
we have carried out a number of both in vitro and in vivo 
studies to assess the effects of the PAD inhibitors in relation 
to different CNS pathologies. Pan-PAD inhibitor Cl-amidine 
was shown by us to significantly reduce spinal cord damage 
in vivo in a chick model, significantly reducing cell death, 
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reducing histone H3 deimination and promoting spinal cord 
regeneration (Lange et al., 2011). Similar protective effects 
for Cl-amidine were thereafter confirmed in an in vivo acute 
murine CNS injury model of neonatal HIE, also in combination 
with LPS stimulation, which mimics combinatory bacterial 
infection with HIE. Following pan-PAD inhibitor treatment, 
significantly reduced neuronal tissue loss and neuronal cell 
death, alongside reduced microglial activation and reduction 
in histone H3 deimination was observed in the brains of Cl-
amidine treated HIE animals, compared with sham brains 
(Lange et al., 2014). In relation to our studies on brain 
cancers, human in vitro models of GBM revealed that pan-
PAD inhibitor Cl-amidine modulated EV release and EV-cargo 
differently, depending on GBM cell lines used, but overall 
changed EV-cargo to anti-oncogenic signatures. Such effects 
were also assessed in combination with temozolomide, the 
main chemotherapeutic agent for GBM, and found to sensitize 
cells to temozolomide treatment. Furthermore we found 
that Cl-amidine modulated post-translational deimination 
levels of histone H3, as well as deimination of prohibitin, a 
multifaceted protein with roles in mitochondrial architecture 
and housekeeping (Kosgodage et al., 2018). In a subsequent 
study, we assessed PAD2, PAD3 and PAD4 specific inhibitors in 
the same GBM cell lines and showed that these had selective 
effects on the different GBM cell lines, which also were shown 
to differ correspondingly in their proportional expression 
of the different PAD isozymes. The PAD isozyme-specific 
inhibitors showed cell-line specific effects on GBM invasion 
ability, selective effects on the modulation of EV release and a 
shift to more anti-oncogenic signatures of EV-cargo, including 
the reduction of the pro-oncogenic micro-RNA21, reduction 
in the hypoxia-related micro-RNA210 and elevation in micro-
RNA126, which has been shown to have a positive correlation 
with improved outcomes in GBM. Therefore, variability in PAD 
isozyme-specific expression, identified in the different GBM 
cell lines, may lay the foundations for novel personalized 
treatment approaches, using selective PAD-isozyme inhibitors, 
according to GBM subtype. 
Future Treatment Approaches with 
Peptidylarginine Deiminases and Extracellular 
Vesicles as Targets
Future approaches for clinical PAD inhibitor treatment, both 
aimed at modulating total deimination via pan-PAD inhibitors, 
or a narrower range of deimination targets using PAD 
isozyme-specific inhibitors, still requires further refinement 
and optimization of PAD-inhibitor treatment. This also refers 
to testing in more translatable animal models for clinical 
studies relating to CNS pathologies. The use of deimination 
signatures in EVs are furthermore a newly identified liquid 
biopsy tool for early PD diagnosis, prior to motor symptoms, 
and offers a promising new non-invasive blood test, which 
can reflect pathological deimination changes in the brain 
vasculature, indicative also of changes in brain glymphatics. 
The development of such PAD-related biomarkers in other 
neurodegenerative diseases is still a relatively unexplored 
area that warrants more research, based on the clear 
indications that PADs and deimination are critical factors 
in neuroinflammation and disease progression. The role 
for modulation of EV-release and EV-cargo also remains a 
relatively understudied field (Lange et al., 2017a; Sancandi et 
al., 2020). Furthermore, the application of MSC-derived EVs is 
an increasingly growing field of interest and has been shown 
great promise in a number of CNS injury models (Ophelders 
et al., 2016; Dabrowska et al., 2019; Kodali et al., 2019; Sisa 
et al., 2020). Roles for PADs and associated pharmacological 
manipulation in acute CNS injury also requires further in depth 
investigation, alongside refined assessment of application 
at different time windows in relation to different CNS injury 
scenarios. This also includes effects on PAD-mediated 
modulation of EVs and identification of EV-specific signatures, 
which yet have to be assessed in relation to PAD-mediated 
mechanisms in acute CNS injury and may therefore provide 
useful information for processes contributing to CNS insult 
and repair. Furthermore, understanding of the contribution 
of PADs in pathways relating to chronic neuropathologies in 
the wake of a primary insult, including those resulting from 
traumatic and blast head injury, as well as following viral 
infection also needs to be better understood and may aid the 
development of novel biomarkers and treatment approaches. 
In brain cancers, such as GBM, roles for PADs have only 
recently been identified and furthermore EV regulation 
in GBM is a current topic of focus, where PAD-mediated 
EV regulation has only recently been described by our 
group (Kosgodage et al., 2018; Uysal-Onganer et al., 2020). 
Therefore, further understanding of PADs and PAD isozyme-
specific regulation of protein deimination and downstream 
processes, including EV release and EV-cargo, warrants further 
exploration for the development of reliable biomarkers 
and for effective treatment strategies in GBM, also offering 
tailored treatment for this heterogeneous brain cancer. 
Furthermore, in the current SARS-CoV-2 pandemic, a wide 
range of unexplained neurological conditions has received 
increased attention. This includes acute cerebrovascular 
disease, stroke, encephalopathy, encephalitis, CNS vasculitis 
and acute neuropathies such as Guillain-Barré syndrome (Ellul 
et al., 2020; Varatharaj et al., 2020). This has prompted a call 
out for the need of studies identifying underlying mechanisms 
(Varatharaj et al., 2020). PADs have recently been assessed 
by our group in SARS-CoV-2 infected patient biopsies from 
multiple organs, indicating roles for the different PAD isozymes 
in the multifaceted symptoms and co-morbidities in COVID-19 
(Arisan et al., 2020). Due to the central roles for PADs in 
the CNS, as discussed in this mini-review, their involvement 
in SARS-CoV-2, as well as other viral infection related 
neurological disease symptoms, may be of considerable 
importance for further investigation, including in relation to 
longer term neurological outcomes in COVID-19 patients.
Summary and Conclusions
In summary, roles for PADs and downstream processes, 
including post-translational deimination and modulation of 
EV release and EV signatures, are of pivotal importance in 
relation to CNS acute injury, neurodegenerative diseases 
and CNS cancers. Modulation of PADs, via selective PAD 
inhibitors, holds much promise for future therapies, both 
for intervention in acute CNS injury and longer-term chronic 
neuro-inflammatory conditions, as well as PAD-mediated 
mechanisms in CNS cancers. Roles for PADs in viral infections 
which lead to neurological symptoms, including in COVID-19, 
also need further investigation. The application of MSC-EVs 
for aiding repair in the injured CNS is also an increasingly 
attractive treatment strategy option, requiring further in 
depth investigation for efficient implementation. The use 
of deimination signatures in biofluids and associated EVs, 
including from plasma and serum, can furthermore provide 
reliable non-invasive tests with information aiding early CNS 
disease diagnosis, reveal information on disease progression 
and response to therapy.
Acknowledgments: The author would like to apologize in advance for not 
being able to accommodate all CNS-related studies in the PAD and EV re-
search fields in the current manuscript, due to formatting regulations for 
a mini-review. 
938  ｜NEURAL REGENERATION RESEARCH｜Vol 16｜No.5｜May 2021
Author contributions: The author completed the manuscript 
independently and approved the final manuscript.
Conflicts of interest: The author declares no conflicts of interest.
Financial support: The work was supported in parts by the University of 
Westminster start-up grant to SL.
Copyright license agreement: The Copyright License Agreement has 
been signed by the author before publication.
Plagiarism check: Checked twice by iThenticate. 
Peer review: Externally peer reviewed. 
Open access statement: This is an open access journal, and articles 
are distributed under the terms of the Creative Commons Attribution-
NonCommercial-ShareAlike 4.0 License, which allows others to remix, 
tweak, and build upon the work non-commercially, as long as appropriate 
credit is given and the new creations are licensed under the identical 
terms.
References
Alghamdi M, Al Ghamdi KA, Khan RH, Uversky VN, Redwan EM (2018) 
An interplay of structure and intrinsic disorder in the functionality of 
peptidylarginine deiminases, a family of key autoimmunity-related 
enzymes. Cell Mol Life Sci 76:4635-4662.
Arisan D, Uysal-Onganer P, Lange S (2020) Putative roles for peptidylarginine 
deiminases in COVID-19. Int J Mol Sci Int 21:4662.
Attilio PJ, Flora M, Kamnaksh A, Bradshaw DJ, Agoston D, Mueller GP (2017) 
The effects of blast exposure on protein deimination in the brain. Oxid Med 
Cell Longev 2017:8398072.
Caprariello AV, Rogers JA, Morgan ML, Hoghooghi V, Plemel JR, Koebel 
A, Tsutsui S, Dunn JF, Kotra LP, Ousman SS, Wee Yong V, Stys PK (2018) 
Biochemically altered myelin triggers autoimmune demyelination. Proc 
Natl Acad Sci U S A 115:5528-5533.
Dabrowska S, Andrzejewska A, Strzemecki D, Muraca M, Janowski M, 
Lukomska B (2019) Human bone marrow mesenchymal stem cell-derived 
extracellular vesicles attenuate neuroinflammation evoked by focal brain 
injury in rats. J Neuroinflammation 16:216.
Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, Kneen R, Defres 
S, Sejvar J, Solomon T (2020) Neurological associations of COVID-19. Lancet 
Neurol doi: 10.1016/S1474-4422(20)30221-0.
Faigle W, Cruciani C, Wolski W, Roschitzki B, Puthenparampil M, Tomas-Ojer P, 
Sellés-Moreno C, Zeis T, Jelcic I, Schaeren-Wiemers N, Sospedra M, Martin 
R (2019) Brain citrullination patterns and T cell reactivity of cerebrospinal 
fluid-derived CD4+ T cells in multiple sclerosis. Front Immunol 10:540.
Gallart-Palau X, Lee BS, Adav SS, Qian J, Serra A, Park JE, Lai MK, Chen CP, 
Kalaria RN, Sze SK (2016)  Gender differences in white matter pathology 
and mitochondrial dysfunction in Alzheimer’s disease with cerebrovascular 
disease. Mol Brain 9:27.
György B, Tóth E, Tarcsa E, Falus A, Buzás EI (2006) Citrullination: a 
posttranslational modification in health and disease. Int J Biochem Cell Biol 
38:1662-1677.
Ishigami A, Masutomi H, Handa S, Nakamura M, Nakaya S, Uchida Y, Saito Y, 
Murayama S, Jang B, Jeon YC, Choi EK, Kim YS, Kasahara Y, Maruyama N, 
Toda T (2015) Mass spectrometric identification of citrullination sites and 
immunohistochemical detection of citrullinated glial fibrillary acidic protein 
in Alzheimer’s disease brains. J Neurosci Res 93:1664-1674.
Jang B, Jeon YC, Shin HY, Lee YJ, Kim H, Kondo Y, Ishigami A, Kim YS, Choi EK 
(2018) Myelin basic protein citrullination, a hallmark of central nervous 
system demyelination, assessed by novel monoclonal antibodies in prion 
diseases. Mol Neurobiol 55:3172-3184.
Jeffrey CJ (2018) Protein moonlighting: What is it, and why is it important? 
Philos Trans R Soc Lond B Biol Sci 373:20160523.
Kholia S, Jorfi S, Thompson PR, Causey CP, Nicholas AP, Inal JM, Lange S (2015) 
A novel role for peptidylarginine deiminases in microvesicle release reveals 
therapeutic potential of PAD inhibition in sensitizing prostate cancer cells 
to chemotherapy. J Extracell Vesicles 4:26192.
Kodali M, Castro OW, Kim DK, Thomas A, Shuai B, Attaluri S, Upadhya R, Gitai D, 
Madhu LN, Prockop DJ, Shetty AK (2019) Intranasally administered human 
MSC-derived extracellular vesicles pervasively incorporate into neurons 
and microglia in both intact and status epilepticus injured forebrain. Int J 
Mol Sci 21:181.
Kosgodage US, Uysal-Onganer P, MacLatchy A, Kraev I, Chatterton NP, Nicholas 
AP, Inal JM, Lange S (2018) Peptidylarginine deiminases post-translationally 
deiminate prohibitin and modulate extracellular vesicle release and 
microRNAs in glioblastoma multiforme. Int J Mol Sci 20:103. 
Lange S, Gallagher M, Kholia S, Kosgodage US, Hristova M, Hardy J, 
Inal JM (2017a) Peptidylarginine deiminases – roles in cancer and 
neurodegeneration and possible avenues for therapeutic intervention 
via modulation of exosome and microvesicle (EMV) release? Int J Mol Sci 
18:1196.
Lange S, Gögel S, Leung KY, Vernay B, Nicholas AP, Causey CP, Thompson 
PR, Greene ND, Ferretti P (2011) Protein deiminases: new players in the 
developmentally regulated loss of neural regenerative ability. Dev Biol 
355:205-214.
Lange S, Rocha-Ferreira E, Thei L, Mawjee P, Bennett K, Thompson PR, 
Subramanian V, Nicholas AP, Peebles D, Hristova M, Raivich G (2014) 
Peptidylarginine deiminases: novel drug targets for prevention of neuronal 
damage following hypoxic ischemic insult (HI) in neonates. J Neurochem 
130:555-562.
Lange S, Wray S, Devine M, Matarin M, Hardy J (2017b) Protein deimination in 
protein misfolding disorders–modelled in human induced pluripotent stem 
cells (iPSCs). In: Protein deimination in human health and disease (Nicholas 
AP and Bhattacharya SK, Eds). New York: Springer Science and Business 
Media.
Lazarus RC, Buonora JE, Flora MN, Freedy JG, Holstein GR, Martinelli GP, 
Jacobowitz DM, Mueller GP (2015) Protein citrullination: a proposed 
mechanism for pathology in traumatic brain injury. Front Neurol 6:204.
Magnadóttir B, Hayes P, Hristova M, Bragason BT, Nicholas AP, Dodds AW, 
Guðmundsdóttir S, Lange S (2018) Post-translational protein deimination 
in cod (Gadus morhua L.) ontogeny novel roles in tissue remodelling and 
mucosal immune defences? Dev Comp Immunol 87:157-170.
Mondal S, Thompson PR (2019) Protein arginine deiminases (PADs): 
biochemistry and chemical biology of protein citrullination. Acc Chem Res 
52:818-832.
Moscarello MA, Wood DD, Ackerley C, Boulias C (1994) Myelin in multiple 
sclerosis is developmentally immature. J Clin Invest 94:146-154.
Nicholas AP, Lu L, Heaven M, Kadish I, van Groen T, Accavitti-Loper MA, 
Wewering S, Kofskey D, Gambetti P, Brenner M (2014) Ongoing studies 
of deimination in neurodegenerative diseases using the F95 antibody. 
In: Protein deimination in human health and disease (Nicholas AP and 
Bhattacharya SK, Eds), pp257-280. New York: Springer-Verlag.
Ophelders DR, Wolfs TG, Jellema RK, Zwanenburg A, Andriessen P, Delhaas 
T, Ludwig AK, Radtke S, Peters V, Janssen L, Giebel B, Kramer BW (2016) 
Mesenchymal stromal cell-derived extracellular vesicles protect the fetal 
brain after hypoxia-ischemia. Stem Cells Transl Med 5:754-763.
Sancandi M, Uysal-Onganer P, Kraev I, Mercer A, Lange S (2020) Protein 
deimination signatures in plasma and plasma-EVs and protein deimination 
in the brain vasculature in a rat model of pre-motor Parkinson’s disease. Int 
J Mol Sci 21:2743.
Sisa C, Kholia S, Naylor J, Herrera Sanchez MB, Bruno S, Deregibus MC, 
Camussi G, Inal JM, Lange S, Hristova M (2019) Mesenchymal stromal cell 
derived extracellular vesicles reduce hypoxia-ischaemia induced perinatal 
brain injury. Front Physiol 10:282.
Uysal-Onganer P, MacLatchy A, Mahmoud R, Kraev I, Thompson PR, Inal JM, 
Lange S (2020) Peptidylarginine deiminase isozyme-specific PAD2, PAD3 
and PAD4 inhibitors differentially modulate extracellular vesicle signatures 
and cell invasion in two glioblastoma multiforme cell lines. Int J Mol Sci 
21:1495.
Varatharaj A, Thomas N, Ellul MA, Davies NWS, Pollak TA, Tenorio EL, Sultan M, 
Easton A, Breen G, Zandi M, Coles JP, Manji H, Al-Shahi Salman R, Menon 
DK, Nicholson TR, Benjamin LA, Carson A, Smith C, Turner MR, Solomon T, 
et al. (2020) Neurological and neuropsychiatric complications of COVID-19 
in 153 patients: A UK-wide surveillance study. Lancet Psychiatry doi: 
10.1016/S2215-0366(20)30287-X.
Varderidou-Minasian S, Lorenowicz MJ (2020) Mesenchymal stromal/
stem cell-derived extracellular vesicles in tissue repair: challenges and 
opportunities. Theranostics 10:5979-5997.
C-Editors: Zhao M, Li JY; T-Editor: Jia Y
Review
